Form 4 for CMPX Compass Therapeutics, Inc.

Accepted 2022-08-02 00:00:00 ET · period of report 2022-08-01 · accession 0001171843-22-005231 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2022-08-02	2022-08-01	CMPX	Schuetz Thomas J.	CEO, Dir	P - Purchase	$2.58	+15.0K	5.35M	+0.3%	+$38.7K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-08-01	P	A	15,000	$2.58	5,346,873	D	—	—	(F1) The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.62 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. (F2) 170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022.